HOME >> BIOLOGY >> NEWS
Finding a cure for cancer: The holy grail of science

To find a cure for cancer, the modern-day plague of our society is synonymous to finding the holy grail of science.

At a recent EuroDYNA conference in Brno, Czech Republic, scientists from around Europe came together to share their research carried out in the field of genetics and cell nucleus architecture. A greater understanding of the body's building blocks might ultimately lead to a better understanding of human disease.

Understanding DNA damage
Jiri Bartek from the Danish Cancer Society in Copenhagen in Denmark, is one step closer to understanding the route of cancer through his work on cell response to DNA damage. By using a UV laser to damage DNA strands inside tumour cells, the Copenhagen team is able to directly observe the different checkpoints in the cell.

Each time a cell divides its genetic information must be doubled in order for the genes to remain the same. A cell that is about to become tumorous can not make this genome replication and division without errors. To spot errors in the genetic material cells have evolved mechanisms to slow down or block cell division (so called cell-cycle checkpoints), promote DNA repair, or eliminate damaged, hazardous cells by engaging a cellular suicide program. How cells make the choice between life and death in response to DNA damage is critical not only for the fate of each cell, but also for avoiding life-threatening diseases such as cancer.

In cells with an early pre-tumorous change, the entire checkpoint network is activated. The system puts an end to such cells or blocks their division by a process of cellular senescence. On the other hand, defects in the DNA damage response machinery, or a phenomenon of checkpoint adaptation (when the cell arrest is long-term and not irreversible) may allow the cell to escape from the DNA damage-imposed blockade and despite its damaged DNA, it may multiply. This can give birth to a tumour.

Bartek and his team
'"/>

Contact: Sofia Valleley
svalleley@esf.org
33-388-762-149
European Science Foundation
21-Nov-2006


Page: 1 2 3 4

Related biology news :

1. Finding protection from tumor growth in unexpected places
2. Finding the white wine difference
3. Finding an answer to Darwins Dilemma
4. Finding the right mix: A biomaterial blend library
5. Finding paves way for better treatment of autoimmune disease
6. Finding about cellular microtubule rigidity could lead to development of new nano-materials
7. Findings by Einstein scientists reveal possible strategy against obesity, diabetes and infertility
8. Finding of a new molecular marker of resistance to chemotherapy in breast cancer
9. Finding a cellular Neverland: How stem cells stay childlike
10. Finding a virus is not all bad news
11. Finding life on Mars and outer space begins by examining Earths inner space

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
Cached News: